KBC Group’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-843
| Closed | -$16K | – | 1861 |
|
|
2023
Q3 | $16K | Sell |
843
-217
| -20% | -$4.5K | ﹤0.01% | 1899 |
|
|
2023
Q2 | $28K | Hold |
1,060
| – | – | ﹤0.01% | 1451 |
|
|
2023
Q1 | $30K | Hold |
1,060
| – | – | ﹤0.01% | 1464 |
|
|
2022
Q4 | $31K | Hold |
1,060
| – | – | ﹤0.01% | 1472 |
|
|
2022
Q3 | $25K | Hold |
1,060
| – | – | ﹤0.01% | 1493 |
|
|
2022
Q2 | $24K | Buy |
+1,060
| New | +$23.6K | ﹤0.01% | 1515 |
|
|
2021
Q1 | – | Sell |
-1,539
| Closed | -$70K | – | 1284 |
|
|
2020
Q4 | $70K | Hold |
1,539
| – | – | ﹤0.01% | 1188 |
|
|
2020
Q3 | $54K | Hold |
1,539
| – | – | ﹤0.01% | 1176 |
|
|
2020
Q2 | $58K | Sell |
1,539
-7,015
| -82% | -$231K | ﹤0.01% | 1203 |
|
|
2020
Q1 | $247K | Sell |
8,554
-18,577
| -68% | -$751K | ﹤0.01% | 988 |
|
|
2019
Q4 | $1.41M | Buy |
27,131
+12,266
| +83% | +$713K | 0.01% | 786 |
|
|
2019
Q3 | $816K | Buy |
14,865
+3,397
| +30% | +$174K | 0.01% | 937 |
|
|
2019
Q2 | $466K | Sell |
11,468
-12,472
| -52% | -$455K | ﹤0.01% | 1080 |
|
|
2019
Q1 | $724K | Buy |
23,940
+12,969
| +118% | +$444K | 0.01% | 966 |
|
|
2018
Q4 | $369K | Sell |
10,971
-7,350
| -40% | -$265K | ﹤0.01% | 999 |
|
|
2018
Q3 | $773K | Buy |
+18,321
| New | +$724K | 0.01% | 1000 |
|
|
2018
Q2 | – | Sell |
-6,607
| Closed | -$329K | – | 1292 |
|
|
2018
Q1 | $329K | Sell |
6,607
-6,835
| -51% | -$386K | ﹤0.01% | 1052 |
|
|
2017
Q4 | $725K | Hold |
13,442
| – | – | 0.01% | 890 |
|
|
2017
Q3 | $780K | Sell |
13,442
-5,411
| -29% | -$283K | 0.01% | 872 |
|
|
2017
Q2 | $930K | Sell |
18,853
-8,210
| -30% | -$378K | 0.01% | 797 |
|
|
2017
Q1 | $1.18M | Sell |
27,063
-399
| -1% | -$19K | 0.01% | 809 |
|
|
2016
Q4 | $1.34M | Buy |
27,462
+11,273
| +70% | +$521K | 0.01% | 761 |
|
|
2016
Q3 | $775K | Buy |
16,189
+8,050
| +99% | +$398K | 0.01% | 843 |
|
|
2016
Q2 | $437K | Buy |
8,139
+7,740
| +1,940% | +$365K | 0.01% | 913 |
|
|
2016
Q1 | $18K | Hold |
399
| – | – | ﹤0.01% | 1232 |
|
|
2015
Q4 | $15K | Buy |
+399
| New | +$15.3K | ﹤0.01% | 1241 |
|
|
2014
Q4 | – | Sell |
-3,841
| Closed | -$141K | – | 1429 |
|
|
2014
Q3 | $141K | Hold |
3,841
| – | – | ﹤0.01% | 1071 |
|
|
2014
Q2 | $178K | Hold |
3,841
| – | – | ﹤0.01% | 1089 |
|
|
2014
Q1 | $158K | Hold |
3,841
| – | – | ﹤0.01% | 1032 |
|
|
2013
Q4 | $147K | Buy |
+3,841
| New | +$119K | ﹤0.01% | 1069 |
|
Other funds holding ANIK
TI
CP
BFM
CM
KBC Group's ANIK Position: Q4 2023 in Review
KBC Group sold out of Anika Therapeutics (ANIK) in Q4 2023, closing a stake of 843 shares — an estimated $16K sold.
KBC Group first reported a position in ANIK in Q4 2013 and held it in 30 quarters. The position peaked at $1.41M in Q4 2019. 117 funds tracked by Wall St. Rank hold ANIK as of Q4 2023.
- KBC Group reported no remaining Anika Therapeutics position as of Q4 2023 after selling out during the quarter.
- KBC Group sold 843 Anika Therapeutics shares in Q4 2023, an estimated $16K.
- KBC Group first reported a position in Anika Therapeutics in Q4 2013 and held it in 30 quarters.
- KBC Group's Anika Therapeutics position peaked at $1.41M in Q4 2019.
- 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2023.
Based on KBC Group's 13F filing for Q4 2023, filed 13 Feb 2024.